Antimetabolites reduce the activities of enzymes with short half-lives in addition to inhibiting their specific targets.
Weber
G
G
Laboratory for Experimental Oncology, Indiana University School of Medicine, Indianapolis 46202-5200, USA.
Prajda
N
N
Singhal
R L
RL
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001853:Bone Marrow / Q000187:drug effects / Q000201:enzymology; D003513:Cycloheximide / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005472:Fluorouracil / Q000494:pharmacology; D006207:Half-Life; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology; D008727:Methotrexate / Q000494:pharmacology; D011355:Prodrugs / Q000494:pharmacology; D011687:Purines / Q000378:metabolism; D011743:Pyrimidines / Q000378:metabolism; D012254:Ribavirin / Q000031:analogs & derivatives / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects
D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; D007555:Isoxazoles; D011355:Prodrugs; D011687:Purines; D011743:Pyrimidines; D012254:Ribavirin; D003513:Cycloheximide; C006303:acivicin; D005472:Fluorouracil; C033706:tiazofurin; D008727:Methotrexate